Drug Trial Radar · NCT07348692
Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,195
Planned (sponsor's estimate)
Start
Jan 20, 2026
Primary completion
Jun 7, 2027
Study completion May 29, 2028
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jan 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 42 days, up to 89 days
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase 3 randomized, modified double-blind study whose purpose is to measure whether 3 lots of the investigational pneumococcal vaccine PCV21 can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) in a similar way (ie, same immune response) when they are given to infants aged from approximately 2 months (42 to 89 days) and are safe compared to a licensed 20-valent pneumococcal vaccine (20vPCV) (Prevnar 20™). The study duration per participant will be up to approximately 17 months. The study vaccines (either PCV21 or 20vPCV) will be administered at approximately 2, 4, 6 and 12 months of age. Cohort A will include randomization to three PCV21 formulation groups or one 20vPCV comparator group (Group 1-4, approximately 896 total participants), whereas Cohort B will include randomization to three PCV21 formulation groups only (Groups 1-3, approximately 1299 total participants). Routine pediatric vaccines will be given as per local recommendations. There will be 6 study visits: Visit (V)01, V02 separated from V01 by 60 days, V03 separated from V02 by 60 days, V04 separated from V03 by 30 days, V05 at 12 months of age, V06 separated from V05 by 30 days
Conditions
- Pneumococcal Immunization
- Healthy Volunteers
Interventions
PCV21 vaccineBiological
Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
20vPCV licensed vaccineBiological
Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Primary outcomes
What the sponsor says the trial is designed to measure.
- For all participants: Serotype specific Immunoglobulin g (IgG) Geometric Mean Concentration (GMC)Time frame: 30 days after the third dose of PCV21 vaccine
Locations
25 sites in 4 countries. Site status is shown where the registry gives one.
Northwest Arkansas Pediatric Clinic- Site Number : 8400039
Fayetteville, Arkansas · Recruiting
Matrix Clinical Research - Huntington Park- Site Number : 8400029
Huntington Park, California · Recruiting
Community Clinical Research- Site Number : 8400030
Los Angeles, California · Recruiting
Matrix Clinical Research - Los Angeles- Site Number : 8400028
Los Angeles, California · Recruiting
PAS Research - Tampa- Site Number : 8400034
Tampa, Florida · Recruiting
Kentucky Pediatric Research- Site Number : 8400036
Bardstown, Kentucky · Recruiting
Michigan Institute of Research- Site Number : 8400004
Allen Park, Michigan · Recruiting
Nappi Wellness Institute\t- Site Number : 8400037
Syracuse, New York · Recruiting
Tribe Clinical Research At Neighbors Pediatrics- Site Number : 8400008
Charleston, South Carolina · Recruiting
Parkside Pediatrics - Simpsonville- Site Number : 8400005
Simpsonville, South Carolina · Recruiting
Tribe Clinical Research - Spartanburg- Site Number : 8400026
Spartanburg, South Carolina · Recruiting
PAS Research - Children's Care Clinic- Site Number : 8400035
Edinburg, Texas · Recruiting
Pediatric Center - Richmond- Site Number : 8400038
Richmond, Texas · Recruiting
Rio Clinical Trials - Canyon View- Site Number : 8400031
Ogden, Utah · Recruiting
Investigational Site Number : 3400001
San Pedro Sula, Honduras · Recruiting
Investigational Site Number : 3400002
Tegucigalpa, Honduras · Recruiting
Investigational Site Number : 3400003
Tegucigalpa, Honduras · Recruiting
Investigational Site Number : 6300005
Guayama, Puerto Rico · Recruiting
Investigational Site Number : 6300006
San Juan, Puerto Rico · Recruiting
Investigational Site Number : 6300007
Trujillo Alto, Puerto Rico · Recruiting
Investigational Site Number : 7640002
Bangkok, Thailand · Recruiting
Investigational Site Number : 7640004
Chiang Mai, Thailand · Recruiting
Investigational Site Number : 7640003
Hat Yai, Thailand · Recruiting
Investigational Site Number : 7640001
Khon Kaen, Thailand · Recruiting
Investigational Site Number : 7640005
Pathum Wan, Thailand · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.